

Subba Digumarthy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11562517/publications.pdf>

Version: 2024-02-01

25
papers

10,554
citations

933447

10
h-index

752698

20
g-index

25
all docs

25
docs citations

25
times ranked

13457
citing authors

#	ARTICLE	IF	CITATIONS
1	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. <i>Journal of Thoracic Oncology</i> , 2022, 17, 399-410.	1.1	151
2	Abstract 3580: Integrative genomics of checkpoint blockade response in advanced non-small cell lung cancer. <i>Cancer Research</i> , 2022, 82, 3580-3580.	0.9	0
3	Phase I/II investigator-initiated study of olaparib and temozolomide in SCLC: Updated analysis and CNS outcomes.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8565-8565.	1.6	1
4	Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic ROS1-rearranged lung cancers.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9049-9049.	1.6	0
5	Abstract LB197: An SU2C-Mark Foundation Lung collaborative update: integrative genomics identifies distinct transcriptional states associated with checkpoint blockade resistance. , 2021, , .		0
6	Type I Collagenâ€‘targeted Positron Emission Tomography Imaging in Idiopathic Pulmonary Fibrosis: First-in-Human Studies. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 258-261.	5.6	41
7	Phase 2 study of tremelimumab plus durvalumab for previously-treated malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 8549-8549.	1.6	9
8	Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score â‰¥90%.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9111-9111.	1.6	4
9	Longitudinal analysis of plasma ALK mutations during treatment with next-generation ALK inhibitors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9068-9068.	1.6	0
10	Efficacy of platinum-pemetrexed combination chemotherapy in ALK<i>+</i> non-small cell lung cancer refractory to second-generation ALK TKIs.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9067-9067.	1.6	0
11	Radiation dose reduction in chest dual-energy computed tomography: effect on image quality and diagnostic information. <i>Radiologia Brasileira</i> , 2018, 51, 377-384.	0.7	9
12	Assessment of chest CT at CTDI_{vol} less than 1â€‘mGy with iterative reconstruction techniques. <i>British Journal of Radiology</i> , 2017, 90, 20160625.	2.2	10
13	Multifocal adenocarcinoma of the lung: Factors predictive for local therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20041-e20041.	1.6	1
14	<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Nonâ€‘Small Cell Lung Cancer: A Retrospective Analysis. <i>Clinical Cancer Research</i> , 2016, 22, 4585-4593.	7.0	977
15	Primary Paratracheal Leiomyoma: Increased Preoperative Diagnostic Specificity With Magnetic Resonance Imaging. <i>Annals of Thoracic Surgery</i> , 2016, 102, e151-e154.	1.3	2
16	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in<i>ALK</i>-Rearranged Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1118-1133.	9.4	919
17	Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib. <i>JAMA Oncology</i> , 2016, 2, 541.	7.1	49
18	Heterogeneity Underlies the Emergence of <i>EGFR</i>T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. <i>Cancer Discovery</i> , 2015, 5, 713-722.	9.4	429

#	ARTICLE	IF	CITATIONS
19	Variation in mechanisms of acquired resistance (AR) among EGFR-mutant NSCLC patients with more than one post-resistant biopsy.. Journal of Clinical Oncology, 2014, 32, 8053-8053.	1.6	6
20	Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Oncologist, 2013, 18, 1214-1220.	3.7	119
21	Potential Pitfall in the Assessment of Lung Cancer with FDG-PET/CT: Talc Pleurodesis Causes Intrathoracic Nodal FDG Avidity. Lung Cancer International, 2013, 2013, 1-6.	1.2	6
22	Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI).. Journal of Clinical Oncology, 2012, 30, 7524-7524.	1.6	9
23	Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors. Science Translational Medicine, 2011, 3, 75ra26.	12.4	2,938
24	Detection of Mutations in <i>EGFR</i> in Circulating Lung-Cancer Cells. New England Journal of Medicine, 2008, 359, 366-377.	27.0	1,602
25	Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature, 2007, 450, 1235-1239.	27.8	3,272